Vascular Dynamics said early this month it tapped former NuVasive Inc. (NSDQ:NUVA) exec and Ellipse Technologies CEO Ed Roschak as its new president and chief executive.
Prior to joining Mountain View, Calif.-based Vascular Dynamics, Roschak served as prez and CEO of Ellipse Technologies, which he saw through a $410 million acquisition by NuVasive. He then took up a position as CEO of NuVasive’s specialized orthopedics business.
“We are fortunate that Ed has decided to join the VDI Team as CEO. He has extensive experience in managing the IDE/PMA process with the FDA, raising capital to finance complex clinical studies, managing a rapid revenue ramp for novel, clinically superior devices and successfully guiding companies through the exit process. These skills make Ed an excellent fit for Vascular Dynamics as we begin the CALM 2 IDE-approved, pivotal clinical study in the U.S., maximize the value of the Expedited Access Pathway for the VDI Mobius system granted to us by the FDA, and prepare for worldwide commercialization,” VDI chair Michael Henson said in a prepared statement.
Before his seven years at Ellipse, Roschak held positions at pulmonology startup Broncus Technology, which spun out Asthmatx which was later acquired by Boston Scientific (NYSE:BSX).
“The use of VDI’s MobiusHD device in the first 68 patients with resistant hypertension has produced outstanding results, exceeding anything published to date by alternative devices. I am excited to join the VDI team as we begin to execute our FDA-approved pivotal trial. If we are successful, MobiusHD has the potential to become a revolutionary treatment option for patients suffering from this life-threatening disease,” Roschak said in a press release.
Hologic COO Compton to step away
Hologic (NSDQ:HOLX) said early this month that its chief operating officer Eric Compton will step away from the company, effective December 31.
The Marlborough, Mass.-based company did not provide details of the separation, but said that the separation “constitutes a ‘termination without cause,'” according to an SEC filing posted earlier this month.
Hologic said that Compton will remain on as a consultant to the company through the 2018 year as part of his transition agreement.
Compton joined the company in 2014 as COO, after having spent nearly 20 years with Johnson & Johnson (NYSE:JNJ) in various leadership positions, according to Hologic’s website.
Cutera taps ex-Tria Beauty CFO Gardiner as chief finance exec
Cutera said early this month it appointed Sandra Gardiner as chief financial officer and exec VP, which she had been operating as on a consulting basis since July 12.
Prior to the appointment at Cutera, Gardiner operated as CFO and finance VP at laser-based aesthetic device company Tria Beauty, joining in 2015 and staying on until its acquisition in April 2017.
“We’re delighted to welcome Sandy to this permanent role at Cutera and to our Executive Leadership Team as our CFO. Sandy is equipped with a strong healthcare and device background, coupled with the financial acumen and acuity to manage our financial strategy. In her short time in the consulting CFO position, she’s made incredible progress, and had a significant impact on, scaling our finance organization for Cutera’s future. I previously worked with Sandy and know she will help drive performance, expand our portfolio, and manage our financial architecture in a sustainable manner,” Cutera CEO James Reinstein said in a press release.
Gardiner has also served as CFO of both Vermillion and Lipid Sciences, as well as Asante Solutions, Aptus Endosystems and Ventus Medical, the Brisbane, Calif.-based company said.
“I am thrilled to join the exceptional team at Cutera on a permanent basis. In the short time I’ve been associated with the team at Cutera, it’s clear we share a passion of innovative products, while focusing on growth that will lead us to even greater success as a company,” Gardiner said in a prepared statement.
Tandem Diabetes CFO Cajigas steps down, Vosseller steps up
Tandem Diabetes Care (NSDQ:TNDM) said last week its CFO and exec VP John Cajigas will retire December 31 and will be replaced by current senior finance VP Leigh Vosseller, effective January 1.
Vosseler joined Tandem in 2013 as finance VP, and previously served as VP and CFO at Novartis‘s (NYSE:NVS) Genoptix, San Diego, Calif.-based Tandem Diabetes said.
“I want to thank John for his many contributions to Tandem over the past 10 years and wish him the best of luck in his future endeavors. Leigh brings a passion for leading teams, delivering results, and providing financial stewardship and discipline that makes her ideally suited for this expanded role. With our positive sales momentum in the fourth quarter, and our anticipation of key business inflection points in 2018, we expect Leigh will play a pivotal role as we drive toward sustained profitable growth,” prez & CEO Kim Blickenstaff said in a prepared statement.
Presbia announces exec chair, prez & CEO departure amid refocusing efforts
Presbia (NSDQ:LENS) yesterday announced a number of changes to its upper management, including the resignation of its exec chair Randy Thurman and prez & CEO Todd Cooper, with Mark Yung stepping into both the exec chair and CEO role.
The company said that Yung has previously held positions as chairman, CEO and senior management at other technology and manufacturing companies.
The move comes as the company looks to re-order its operational priorities to focus on FDA approval and its ongoing clinical and commercial efforts in Germany and South Korea.
“The board thanks Randy Thurman and Todd Cooper for their dedicated leadership at Presbia. This is an exciting time to join Presbia as it advances through to its final PMA module submission, and to assist in making the Flexivue Microlens available as an FDA-approved optical lens implant to over 1.8 billion presbyopes globally,” Yung said in a press release.
Dublin, Ireland-based Presbia said it has also received an investment proposal from Orchard Capital Corporation, an affiliate of its majority shareholder, to invest up to $5 million in the company’s perferred shares.
The company said that this, with existing cash-on-hand and a reduced burn rate, will fund its operations for the entirety of 2018 and through its anticipated FDA approval of the Flexivue Microlens.
- RIP Encision product dev VP Biggs
- Regentys taps Wexner as chief med officer
- WishBone Medical appoints Capdevielle as chief strategy officer
- Halyard COO Lowery to step down after successful CEO transition
- NuVasive hires Piccirillo to lead global surgeon education platform